Chinese medical journal
-
Chinese medical journal · May 2023
Multicenter StudyEfficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. ⋯ LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.
-
Chinese medical journal · Apr 2023
Multicenter Study Clinical TrialLow diastolic blood pressure and adverse outcomes in inpatients with acute exacerbation of chronic obstructive pulmonary disease: A multicenter cohort study.
Although intensively studied in patients with cardiovascular diseases (CVDs), the prognostic value of diastolic blood pressure (DBP) has little been elucidated in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). This study aimed to reveal the prognostic value of DBP in AECOPD patients. ⋯ Chinese Clinical Trail Registry, No. ChiCTR2100044625.
-
Chinese medical journal · Apr 2023
Letter Multicenter Study Observational StudyMulti-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study.
-
Chinese medical journal · Mar 2023
Multicenter StudyImpact of baseline blood pressure on all-cause death in patients with atrial fibrillation: results from a multicenter registry study.
The ideal blood pressure (BP) target for patients with atrial fibrillation (AF) is still unclear. The present study aimed to assess the effect of the baseline BP on all-cause mortality in patients with AF. ⋯ Having a baseline SBP ≤110 mmHg or DBP <70 mmHg was associated with a significantly higher risk of all-cause mortality in patients with AF. An excessively low BP may not be an optimal target for patients with AF.